COVID-19 and EaD Publications

Published Studies on COVID-19 and Eosinophil-associated Disease




  • Of 102 EGID patients in Italy , none had COVID-19 nor had recurrence of their primary disease or worsening of their disease during the SARS-C0V2 outbreak. Overall, COVID-19 had a limited clinical impact on patients with EGIDs. The degree of education and sex, but not the fact of living in a lockdown area, influenced the perception of SARS-CoV-2 infection.


  • A letter to the editor describes 36 adult patients with EoE, in which none of them were hospitalized for COVID-19 (SARS-COV2). The author suggests that this adds further evidence that eosinophils may be protective against severe COVID-19.


  • A study showed evidence that adults and children with EoE may be protected at the molecular level from COVID19 disease.


  • A review article of what is known about COVID-19 describes that the research is showing that people with eosinophil-associated disorders do not seem to be at increased risk for severe disease from Covid19 and that mRNA based vaccines for COVID-19 are not associated with higher levels of complications for people with eosinophil-associated diseases.


  • This is a small survey study of people with eosinophilic gastrointestinal disease (EoE, EGE and EC) which showed that individuals with these diseases do not appear to have an increased morbidity or mortality for SARS-COV2.


  • A journal article describes the first known case of COVID-19 in a person with EoE in a hospital in Italy. He was not hospitalized nor did he require any therapy for breathing complications.


  • A study showed that telemedicine visits were found to be an effective way of providing care to children with EoE.